Skip to main content

Table 1 Demographic characteristics and disease history, stratified by treatment status

From: Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents

Characteristic, n (%)

All

(N = 280)

Currently treated

Previously treated with ERT

(n = 9)

Treatment naïve

(n = 28)

Other

(n = 9)

Agalsidase beta

(n = 189)

Agalsidase alfa

(n = 19)

Migalastat

(n = 26)

Gender

       

 Female

191 (68)

120 (63)

10 (53)

19 (73)

9 (100)

27 (96)

6 (67)

 Male

88 (31)

68 (36)

9 (47)

7 (27)

0 (0)

1 (4)

3 (33)

 Non-conforming

1 (0)

1 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Age group

       

 18−44 years

124 (44)

82 (43)

12 (63)

9 (35)

5 (56)

11 (39)

5 (56)

 45−64 years

118 (42)

82 (43)

6 (32)

9 (35)

3 (33)

14 (50)

4 (44)

 ≥65 years

38 (14)

25 (13)

1 (5)

8 (31)

1 (11)

3 (11)

0 (0)

Education level

       

 Received masters or above

52 (19)

32 (17)

1 (5)

6 (23)

2 (22)

9 (32)

2 (22)

 Finished college

106 (38)

77 (41)

3 (16)

11 (42)

3 (33)

8 (29)

4 (44)

 Finished trade school

27 (10)

19 (10)

4 (21)

1 (4)

1 (11)

1 (4)

1 (11)

 Finished high school/received GED

88 (31)

56 (30)

11 (58)

8 (31)

3 (33)

9 (32)

1 (11)

 Did not finish high school

7 (3)

5 (3)

0 (0)

0 (0)

0 (0)

1 (4)

1 (11)

Employment status

       

 Employed full- or part-time

152 (54)

103 (54)

11 (58)

11 (42)

3 (33)

20 (71)

4 (44)

 Retired

82 (29)

57 (30)

3 (16)

13 (50)

4 (44)

2 (7)

3 (33)

 Not employed or retired

17 (6)

10 (5)

3 (16)

0 (0)

1 (11)

2 (7)

1 (11)

 Student full- or part-time

15 (5)

11 (6)

2 (11)

1 (4)

0 (0)

1 (4)

0 (0)

 Stay-at-home household manager

14 (5)

8 (4)

0 (0)

1 (4)

1 (11)

3 (11)

1 (11)

Health insurance

       

 Commercial/private

157 (56)

108 (57)

10 (53)

12 (46)

5 (56)

18 64)

4 (44)

 Medicare

71 (25)

49 (26)

3 (16)

8 (31)

5 (56)

3 (11)

3 (33)

 Medicaid

29 (10)

19 (10)

4 (21)

3 (12)

2 (22)

0 (0)

1 (11)

 Marketplace

12 (4)

9 (5)

1 (5)

2 (8)

0 (0)

0 (0)

0 (0)

 Military

8 (3)

6 (3)

0 (0)

1 (4)

0 (0)

1 (4)

0 (0)

 Other

27 (10)

19 (10)

1 (5)

2 (8)

1 (11)

4 (14)

0 (0)

 Not insured

4 (1)

1 (1)

0 (0)

0 (0)

0 (0)

2 (7)

1 (11)

Classic FD

       

 Yes

181 (65)

136 (72)

13 (68)

10 (38)

6 (67)

9 (32)

7 (78)

 No

49 (18)

19 (10)

5 (26)

11 (42)

2 (22)

11 (39)

1 (11)

 Not sure

50 (18)

34 (18)

1 (5)

5 (19)

1 (11)

8 (29)

1 (11)

Time since FD diagnosis

       

 <1 year

5 (2)

0 (0)

0 (0)

0 (0)

0 (0)

4 (14)

1 (11)

 1−2 years

24 (9)

15 (8)

6 (32)

2 (8)

0 (0)

1 (4)

0 (0)

 3−5 years

58 (21)

34 (18)

8 (42)

7 (27)

1 (11)

7 (25)

1 (11)

 6−10 years

49 (18)

37 (20)

1 (5)

5 (19)

2 (22)

4 (14)

0 (0)

 >10 years

144 (51)

103 (54)

4 (21)

12 (46)

6 (67)

12 (43)

7 (78)

Physician managing FD

       

 Geneticist

128 (46)

90 (48)

3 (16)

15 (58)

3 (33)

13 (46)

4 (44)

 Nephrologist

63 (23)

48 (25)

5 (26)

2 (8)

3 (33)

4 (14)

1 (11)

 Primary care/family doctor

45 (16)

27 (14)

5 (26)

5 (19)

2 (22)

3 (11)

3 (33)

 Cardiologist

20 (7)

12 (6)

5 (26)

2 (8)

1 (11)

0 (0)

0 (0)

 Other

10 (4)

7 (4)

0 (0)

1 (4)

0 (0)

2 (7)

0 (0)

 Neurologist

8 (3)

5 (3)

1 (5)

1 (4)

0 (0)

1 (4)

0 (0)

 No one

6 (2)

0 (0)

0 (0)

0 (0)

0 (0)

5 (18)

1 (11)

  1. ERT, enzyme replacement therapy; FD, Fabry disease; GED, General Educational Development